RU2010115088A - Композиции на основе line-полипептида и способы их применения - Google Patents
Композиции на основе line-полипептида и способы их применения Download PDFInfo
- Publication number
- RU2010115088A RU2010115088A RU2010115088/15A RU2010115088A RU2010115088A RU 2010115088 A RU2010115088 A RU 2010115088A RU 2010115088/15 A RU2010115088/15 A RU 2010115088/15A RU 2010115088 A RU2010115088 A RU 2010115088A RU 2010115088 A RU2010115088 A RU 2010115088A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- immunogenic composition
- line polypeptide
- polypeptide
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 45
- 229920001184 polypeptide Polymers 0.000 title claims abstract 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 28
- 230000002163 immunogen Effects 0.000 claims abstract 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 11
- 239000002671 adjuvant Substances 0.000 claims abstract 5
- 210000004400 mucous membrane Anatomy 0.000 claims abstract 5
- 102000039446 nucleic acids Human genes 0.000 claims abstract 5
- 108020004707 nucleic acids Proteins 0.000 claims abstract 5
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 5
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 4
- 238000007911 parenteral administration Methods 0.000 claims abstract 4
- 210000001519 tissue Anatomy 0.000 claims abstract 4
- 239000002773 nucleotide Substances 0.000 claims abstract 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 19
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 210000000265 leukocyte Anatomy 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 5
- 230000001717 pathogenic effect Effects 0.000 claims 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 206010038997 Retroviral infections Diseases 0.000 claims 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000016396 cytokine production Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940127073 nucleoside analogue Drugs 0.000 claims 2
- 230000036647 reaction Effects 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- 108010061833 Integrases Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97399307P | 2007-09-20 | 2007-09-20 | |
| US60/973,993 | 2007-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010115088A true RU2010115088A (ru) | 2011-10-27 |
Family
ID=40468692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010115088/15A RU2010115088A (ru) | 2007-09-20 | 2008-09-19 | Композиции на основе line-полипептида и способы их применения |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110046042A1 (enExample) |
| EP (1) | EP2200637A4 (enExample) |
| JP (1) | JP2010539901A (enExample) |
| KR (1) | KR20100075483A (enExample) |
| CN (1) | CN101969987A (enExample) |
| AU (1) | AU2008301888A1 (enExample) |
| BR (1) | BRPI0817209A2 (enExample) |
| CA (1) | CA2700115A1 (enExample) |
| MX (1) | MX2010003110A (enExample) |
| RU (1) | RU2010115088A (enExample) |
| WO (1) | WO2009038756A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5173838B2 (ja) | 2006-02-13 | 2013-04-03 | アレシア・バイオセラピューティクス・インコーポレーテッド | 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列 |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| WO2011005587A1 (en) * | 2009-06-24 | 2011-01-13 | University Of Dubuque | Vaccine compositions and methods of use to protect against infectious disease |
| WO2012048113A2 (en) | 2010-10-07 | 2012-04-12 | The General Hospital Corporation | Biomarkers of cancer |
| WO2014004945A1 (en) * | 2012-06-28 | 2014-01-03 | University Of Louisville Research Foundation, Inc. | Use of protein line-1 orf-1 as a biomarker for cancer |
| AU2013293062A1 (en) | 2012-07-19 | 2014-07-24 | Alethia Biotherapeutics Inc. | Anti-Siglec-15 antibodies |
| EP3161159B1 (en) | 2014-06-25 | 2020-08-05 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| WO2016159377A1 (ja) * | 2015-04-03 | 2016-10-06 | 国立大学法人京都大学 | がんの治療薬のスクリーニング方法 |
| GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| EP4045655A4 (en) * | 2019-10-16 | 2024-02-28 | King Abdullah University Of Science And Technology | METHOD FOR MODULATING HUMAN L1 RETRO TRANSPOSON RNA AND COMPOSITIONS FOR USE THEREIN |
| US20230053473A1 (en) * | 2019-12-26 | 2023-02-23 | The Johns Hopkins University | Enhancing expression of line-1 encoded orf2p for cancer therapeutics |
| EP4159745B1 (en) * | 2020-06-02 | 2025-09-24 | Tokyo Women's Medical University | S100a8-inhibiting peptide and therapeutic drug for disease which containing same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5280108A (en) * | 1991-09-27 | 1994-01-18 | United States Of America | Antibodies to p40 |
| CA2232344C (en) * | 1995-10-20 | 2005-04-05 | University Of Nebraska Board Of Regents | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells |
| CN1315379A (zh) * | 2000-03-27 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人L1因子p40蛋白12和编码这种多肽的多核苷酸 |
| CN1315332A (zh) * | 2000-03-27 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——l1－12和编码这种多肽的多核苷酸 |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US7700359B2 (en) * | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
| CN1339450A (zh) * | 2000-08-21 | 2002-03-13 | 上海博德基因开发有限公司 | 一种新的多肽——转座元蛋白14.41和编码这种多肽的多核苷酸 |
| CN1339478A (zh) * | 2000-08-21 | 2002-03-13 | 上海博德基因开发有限公司 | 一种新的多肽——人l1因子orf2相关蛋白10.78和编码这种多肽的多核苷酸 |
| CN1343776A (zh) * | 2000-09-19 | 2002-04-10 | 上海博德基因开发有限公司 | 一种新的多肽——dna聚合酶9.02和编码这种多肽的多核苷酸 |
| CN1352094A (zh) * | 2000-11-06 | 2002-06-05 | 上海博德基因开发有限公司 | 一种新的多肽——人l1元件类蛋白19.80和编码这种多肽的多核苷酸 |
| CN1425684A (zh) * | 2001-12-19 | 2003-06-25 | 复旦大学 | 一种多肽——人反转录转座40蛋白－12.76和编码这种多肽的多核苷酸 |
| AU2003294236A1 (en) * | 2002-10-25 | 2004-05-25 | Five Prime Therapeutics, Inc. | Methods of use for novel human polypeptides encoded by polynucleotides |
| WO2005012502A2 (en) * | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
| EP1636343B1 (en) * | 2003-05-28 | 2013-08-21 | The Johns-Hopkins University | Synthetic mammalian retrotransposon gene |
-
2008
- 2008-09-19 CA CA2700115A patent/CA2700115A1/en not_active Abandoned
- 2008-09-19 EP EP08832080A patent/EP2200637A4/en not_active Withdrawn
- 2008-09-19 MX MX2010003110A patent/MX2010003110A/es not_active Application Discontinuation
- 2008-09-19 WO PCT/US2008/010883 patent/WO2009038756A2/en not_active Ceased
- 2008-09-19 CN CN2008801164478A patent/CN101969987A/zh active Pending
- 2008-09-19 US US12/677,278 patent/US20110046042A1/en not_active Abandoned
- 2008-09-19 AU AU2008301888A patent/AU2008301888A1/en not_active Abandoned
- 2008-09-19 RU RU2010115088/15A patent/RU2010115088A/ru unknown
- 2008-09-19 JP JP2010525831A patent/JP2010539901A/ja active Pending
- 2008-09-19 KR KR1020107007557A patent/KR20100075483A/ko not_active Withdrawn
- 2008-09-19 BR BRPI0817209-9A2A patent/BRPI0817209A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009038756A2 (en) | 2009-03-26 |
| MX2010003110A (es) | 2010-05-19 |
| CA2700115A1 (en) | 2009-03-26 |
| US20110046042A1 (en) | 2011-02-24 |
| EP2200637A2 (en) | 2010-06-30 |
| BRPI0817209A2 (pt) | 2015-03-10 |
| CN101969987A (zh) | 2011-02-09 |
| EP2200637A4 (en) | 2011-10-19 |
| AU2008301888A1 (en) | 2009-03-26 |
| WO2009038756A3 (en) | 2009-05-14 |
| JP2010539901A (ja) | 2010-12-24 |
| KR20100075483A (ko) | 2010-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9770506B2 (en) | Adjuvant compound | |
| JP2010539901A5 (enExample) | ||
| FI109335B (fi) | Antigeenin kanssa käytettäväksi tarkoitettuja koostumuksia | |
| Ide et al. | Peptide‐loaded dendritic‐cell vaccination followed by treatment interruption for chronic HIV‐1 infection: a phase 1 trial | |
| AU2002331350B2 (en) | Use of biologically active HIV-1 Tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases | |
| RU2009106089A (ru) | Композиции, содержащие полипептид эндогенного ретровируса человека, и способы их применения | |
| US20220111023A1 (en) | Neoepitope rna cancer vaccine | |
| JP2009544614A5 (enExample) | ||
| WO2013182662A1 (en) | Vaccine | |
| RU2010110545A (ru) | Cdh3-пептид и включающее его лекарственное средство | |
| WO2010022740A2 (en) | Hiv-1 envelope polypeptides for hiv vaccine | |
| RU2010110567A (ru) | Пептид foxm1 и включающее его медицинское средство | |
| RU2013112616A (ru) | Пептид cdca1 и включающее его фармацевтическое средство | |
| RU2011138160A (ru) | Пептиды foxmi и вакцины, содержащие их | |
| JP2025003964A (ja) | 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 | |
| RU2011140168A (ru) | Пептиды vangl1 и содержащие их вакцины | |
| JP2013545733A (ja) | ヒト免疫不全ウィルス（ｈｉｖ）の組換えエンベロープ蛋白質及びそれを含むワクチン | |
| EP3458086A1 (en) | Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections | |
| JP2016032439A (ja) | Ｈｔｌｖ−１関連疾患の予防及び／又は治療用ワクチン | |
| WO2025253381A1 (en) | Cyclic gmp-amp synthase variants and use thereof | |
| NZ623869B2 (en) | Improved pam3cys-like lipopeptide adjuvant compound | |
| RU2010133961A (ru) | Укороченная форма белка p17 вич |